Belimumab for refractory manifestations of cutaneous lupus: A multicenter, retrospective observational study of 16 patients

J Am Acad Dermatol. 2020 Dec;83(6):1816-1819. doi: 10.1016/j.jaad.2020.05.058. Epub 2020 May 19.

Affiliations

¹ Université Paris VII, Assistance Publique-Hôpitaux de Paris, Service de dermatologie hôpital Bichat Claude-Bernard, Paris, France.
² Sorbonne Université, Faculté de Médecine Sorbonne Université, Service de Dermatologie et Allergologie, Hôpital Tenon, Paris, France. Electronic address: francois.chasset@aphp.fr.
³ Sorbonne Université, Faculté de Médecine Sorbonne Université, Service de Dermatologie et Allergologie, Hôpital Tenon, Paris, France.

PMID: 32439463
DOI: 10.1016/j.jaad.2020.05.058

No abstract available

Publication types

Letter
Multicenter Study
Observational Study

MeSH terms

Adult
Aged
Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use*
Drug Resistance
Female
Humans
Immunosuppressive Agents / pharmacology
Immunosuppressive Agents / therapeutic use*
Lupus Erythematosus, Cutaneous / diagnosis
Lupus Erythematosus, Cutaneous / drug therapy*
Lupus Erythematosus, Cutaneous / immunology
Male
Middle Aged
Retrospective Studies
Severity of Illness Index
Treatment Outcome
Young Adult

Substances

Antibodies, Monoclonal, Humanized
Immunosuppressive Agents
belimumab